Drug giant Wyeth loses another HRT trial to the tune of $1.5 million

NewsGuard 100/100 Score

Drug giant Wyeth has been ordered by a court in Philadelphia to pay $1 million in compensation to a woman who developed breast cancer after taking the hormone replacement therapy (HRT) Prempro.

The woman's husband was also awarded damages to the tune of $500,000 after it was revealed that the drug was responsible for causing the woman's breast cancer.

It seems that Mary Daniel, aged 60, of Hot Springs, Arkansas, developed breast cancer after taking Prempro for a 16 month period to treat the symptoms of menopause.

Daniel began taking Prempro in late 1999, and was diagnosed with breast cancer in July 2001.

She then underwent two surgeries as well as chemotherapy and radiotherapy for the cancer.

The trial heard evidence that Wyeth had known for decades that the drug was linked with an increased risk of developing breast cancer in postmenopausal women but still failed to provide adequate warnings about such a risk, despite the worldwide use of the drug.

Daniel's lawyer has accused Wyeth of placing financial profit above the safety of patients.

Reports indicate that Wyeth could now be facing as many as 5,000 liability lawsuits over its hormone replacement drugs; this case is only the third lawsuit involving Prempro to reach a verdict.

Wyeth has to date lost two of the three cases but has declined to comment on the latest verdict.

The jury also found Wyeth guilty of conduct which was "malicious, wanton, willful or oppressive or showed reckless indifference to the interest of others" in its failure to provide proper warnings about its HRT drugs, taken by millions of women to treat symptoms of menopause.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tiny DNA circles are key drivers of cancer formation, study suggests